Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evidence-based role of bevacizumab in non-small cell lung cancer.

× No keyword cloud information.

12 in total

Review 1. Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use.

Authors: Ryan D Gentzler; Sarah E Yentz; Jyoti D Patel
Journal: Curr Treat Options Oncol Date: 2013-12

Review 2. Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences.

Authors: Martin J Edelman; Li Mao
Journal: Transl Lung Cancer Res Date: 2013-08

Review 3. Bevacizumab: a review of its use in advanced cancer.

Authors: Gillian M Keating
Journal: Drugs Date: 2014-10 Impact factor: 9.546

4. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

Authors: Rebecca S Heist; Xiaofei Wang; Lydia Hodgson; Gregory A Otterson; Thomas E Stinchcombe; Leena Gandhi; Miguel A Villalona-Calero; Peter Watson; Everett E Vokes; Mark A Socinski
Journal: J Thorac Oncol Date: 2014-02 Impact factor: 15.609

5. Quantification of antiangiogenic treatment effects on tissue heterogeneity in glioma tumour xenograft model using a combination of DCE-MRI and 3D-ultramicroscopy.

Authors: Marco Dominietto; Michael Dobosz; Sandra Bürgi; Anja Renner; Gudrun Zahlmann; Werner Scheuer; Markus Rudin
Journal: Eur Radiol Date: 2016-11-09 Impact factor: 5.315

6. [Combining bevacizumab with endostatin gets better antitumor efficacy in vivo in lung cancer animal model].

Authors: Niu Niu; Baolan Li; Chaoyang Liu; Ying Hu; Xuebing Li; Jie Li; Heling Shi; Haiqing Zhang
Journal: Zhongguo Fei Ai Za Zhi Date: 2013-02

7. Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.

Authors: Mark S Walker; William Wong; Arliene Ravelo; Paul J E Miller; Lee S Schwartzberg
Journal: Health Qual Life Outcomes Date: 2017-08-14 Impact factor: 3.186

Review 8. Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine.

Authors: Samer Tabchi; Normand Blais
Journal: Front Oncol Date: 2017-03-29 Impact factor: 6.244

9. Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer.

Authors: Aleksi Suo; Allison Childers; Adrijana D'Silva; Lars F Petersen; Shannon Otsuka; Michelle Dean; Haocheng Li; Emeka K Enwere; Brant Pohorelic; Alexander Klimowicz; Ivana A Souza; Jawed Hamid; Gerald W Zamponi; DGwyn Bebb
Journal: Oncotarget Date: 2018-01-12

10. Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy.

Authors: Johanna Sápi; Levente Kovács; Dániel András Drexler; Pál Kocsis; Dávid Gajári; Zoltán Sápi
Journal: PLoS One Date: 2015-11-05 Impact factor: 3.240